| CHRS Market Cap History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the CHRS market cap history going back to 11/30/2014:
Also see: CHRS Shares Outstanding History and CHRS YTD Return |
CHRS Market Cap History — Coherus BioSciences Capitalization Over Time
As of 7/31/2026 Coherus BioSciences has a market cap of 217.85 million. Investors often follow the CHRS market cap history to compare the size of the company over time.
This page shows CHRS market capitalization trends over time, with 42 market cap datapoints presented, dating back to 11/30/2014.
| CHRS Market Cap History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CHRS Historical Market Cap: -6.14% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CHRS Stock Price Chart |
| About Coherus Oncology Inc |
| Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. Co. is focused on the research, development and commercialization of immunotherapies to treat cancer. Co.'s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. We show 42 historical shares outstanding datapoints in our CHRS shares outstanding history coverage, used to compute CHRS market cap on those dates. Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing CHRS market cap history over the course of time is important for investors interested in comparing CHRS's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of CHRS versus a peer is one thing; comparing CHRS market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like CHRS can fluctuate over the course of history. With this page we aim to empower investors researching CHRS by allowing them to research the CHRS market cap history. |
| CHRS Current Stock Quote |
Quotes delayed 20 minutes  Free CHRS Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: The Importance of Market Cap | |
|
Video: The Importance of Market Cap
| CHRS Share Performance |
| Market Cap Peers |
| Coherus BioSciences (CHRS) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:
CI Market Cap History CINC Market Cap History CING Market Cap History CKPT Market Cap History CLBS Market Cap History CLDX Market Cap History CLNN Market Cap History CLOV Market Cap History CLPT Market Cap History CLRB Market Cap History More Healthcare companies » |
CHRS Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
